Alzheimer's disease - Subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 1, 2016, Pages 95-113

  Wallin, Anders ^a   Nordlund, Arto ^a   Jonsson, Michael ^a   Blennow, Kaj ^a,b   Zetterberg, Henrik ^a,c   Öhrfelt, Annika ^a   Stålhammar, Jacob ^a   Eckerström, Marie ^a   Carlsson, Mårten ^a   Olsson, Erik ^a   Göthlin, Mattias ^a   Svensson, Johan ^a   Rolstad, Sindre ^a   Eckerström, Carl ^a   Bjerke, Maria ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; cognitive impairment; magnetic resonance; neurochemistry; neuropsychology; subcortical vascular dementia; white matter changes

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ATTENTION DISTURBANCE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COGNITIVE RESERVE; DEMENTIA; DEPRESSION; DISEASE COURSE; EEG ABNORMALITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FOLLOW UP; HUMAN; LANGUAGE DISABILITY; MILD COGNITIVE IMPAIRMENT; NEUROCHEMISTRY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PRIORITY JOURNAL; REVIEW; SUBCORTICAL VASCULAR DISEASE; WHITE MATTER LESION; BLOOD; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DEMENTIA, VASCULAR; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATHOLOGY; PROCEDURES;

ALZHEIMER DISEASE; BIOMARKERS; CLINICAL STUDIES AS TOPIC; CLINICAL TRIALS AS TOPIC; DEMENTIA, VASCULAR; HUMANS; MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDIES AS TOPIC; RESEARCH DESIGN;

EID: 84951569530     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.148     Document Type: Review

References (115)

1. Winblad B, Graf A, Riviere ME, Andreasen N and Ryan JM. Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther 2014; 6: 7
2. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013; 9: e111-e194
3. Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, et al. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr 2014; 26: 543-554
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269
5. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136(Pt 9): 2697-2706
6. Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006; 3: 71-73
7. Yan R and Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014; 13: 319-329
8. Blennow K and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
10. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45: 1161-1168
11. Roman GC, Erkinjuntti T, Wallin A, Pantoni L and Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426-436
12. Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 2012; 43: 2526-2534
13. Wallin A, Ohrfelt A and Bjerke M. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci 2012; 322: 192-196
14. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169-175
15. Zekry D and Gold G. Management of mixed dementia. Drugs Aging 2010; 27: 715-728
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944
17. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23-30
18. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993; 43: 250-260
19. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554
20. McKeith IG, Perry EK and Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53: 902-905
21. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
22. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013; 9: 137-140
23. The LADIS Study Group, Poggesi A, Pantoni L, Inzitari D, Fazekas F, Ferro J, O'Brien J, et al. 2001-2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis 2011; 32: 577-588
24. Blennow K, Wallin A and Gottfries C-G. Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. Int J Geriatr Psychiatry 1991; 6: 147-154
25. Blennow K, Wallin A and Gottfries CG. Confusional symptomatology distinguishes early-and late-onset Alzheimer's disease. Aging 1990; 2: 395-401
26. Wallin A, Blennow K and Gottfries C-G. Subcortical symptoms predominate in vascular dementia. Int J Geriatr Psychiatry 1991; 6: 137-145
27. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S and Wallin A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005; 76: 1485-1490
28. Nordlund A, Rolstad S, Klang O, Lind K, Hansen S and Wallin A. Cognitive profiles of mild cognitive impairment with and without vascular disease. Neuropsychology 2007; 21: 706-712
29. Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, et al. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropsychol Soc 2008; 14: 582-590
30. Nordlund A, Gothlin M and Wallin A. Vascular disease, Alzheimer's disease biomarkers and cognition in mild cognitive impairment: additive or synergetic effects? Dement Geriatr Cogn Disord 2011; 32: 250-256
31. Nordlund A, Rolstad S, Gothlin M, Edman A, Hansen S and Wallin A. Cognitive profiles of incipient dementia in the Goteborg MCI study. Dement Geriatr Cogn Disord 2010; 30: 403-410
32. Nordlund A, Rolstad S, Klang O, Edman A, Hansen S and Wallin A. Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J Neurol Neurosurg Psychiatry 2010; 81: 541-546
33. Wallin A, Blennow K, Uhlemann C, Langstrom G and Gottfries CG. White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia-diagnostic and pathogenetic aspects. Acta Neurol Scand 1989; 80: 518-523
34. Wallin A, Sjogren M, Edman A, Blennow K and Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol 2000; 44: 229-235
35. Jonsson M, Edman A, Lind K, Rolstad S, Sjogren M and Wallin A. Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia. Int J Geriatr Psychiatry 2010; 25: 588-595
36. Lind K, Jonsson M, Karlsson I, Sjogren M, Wallin A and Edman A. Depressive symptoms and white matter changes in patients with dementia. Int J Geriatr Psychiatry 2006; 21: 119-125
37. Eckerstrom C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, et al. Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Goteborg MCI study. J Neurol Sci 2008; 272: 48-59
38. Edman A, Edenbrandt L, Freden-Lindqvist J, Nilsson M and Wallin A. Asymmetric cerebral blood flow in patients with mild cognitive impairment: possible relationship to further cognitive deterioration. Dement Geriatr Cogn Disord Extra 2011; 1: 228-236
39. Eckerstrom C, Olsson E, Klasson N, Bjerke M, Gothlin M, Jonsson M, et al. High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement Geriatr Cogn Disord 2011; 31: 132-138
40. Sjogren M, Gustafson L, Wikkelso C and Wallin A. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord 2000; 11: 275-285
41. Edman A, Matousek M and Wallin A. EEG findings in dementia are related to the parietal lobe syndrome. Dementia 1995; 6: 323-329
42. Matousek M, Brunovsky M, Edman A and Wallin A. EEG abnormalities in dementia reflect the parietal lobe syndrome. Clin Neurophysiol 2001; 112: 1001-1005
43. Edman A, Brunovsky M, Sjogren M, Wallin A and Matousek M. Objective measurement of the alertness level in dementia. Dement Geriatr Cogn Disord 2003; 15: 212-217
44. Sjogren M, Wikkelso C, Ostling S, Wallin A and Blennow K. Biological correlates of clinical subgroups of Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14: 191-197
45. Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG and Svennerholm L. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992; 85: 103-106
46. Rosengren LE, Karlsson JE, Sjogren M, Blennow K and Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-1093
47. Wallin A and Sjogren M. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 2001; 122: 1937-1949
48. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66: 510-516
49. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A and Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 2011; 27: 665-676
50. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009; 28: 348-356
51. Bjerke M, Jonsson M, Nordlund A, Eckerstrom C, Blennow K, Zetterberg H, et al. Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS substudy. Dement Geriatr Cogn Disord Extra 2014; 4: 385-394
52. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, et al. Cerebrospinal fluid biomarkers of white matter lesions-cross-sectional results from the LADIS study. Eur J Neurol 2010; 17: 377-382
53. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39: 1414-1420
54. Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: the LADIS study. Dement Geriatr Cogn Disord 2012; 34: 61-67
55. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I and Svennerholm L. Blood brain barrier function in vascular dementia. Acta Neurol Scand 1990; 81: 318-322
56. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Disord Extra 2011; 1: 31-42
57. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-630
58. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012; 78: 468-476
59. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-345
60. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 2012; 30: 767-778
61. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393
62. Tarkowski E, Blennow K, Wallin A and Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999; 19: 223-230
63. Tarkowski E, Wallin A, Regland B, Blennow K and Tarkowski A. Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand 2001; 103: 166-174
64. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237-243
65. Lind K, Edman A, Nordlund A, Olsson T and Wallin A. Increased saliva cortisol awakening response in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 24: 389-395
66. Quinlan P, Nordlund A, Lind K, Gustafson D, Edman A and Wallin A. Thyroid hormones are associated with poorer cognition in mild cognitive impairment. Dement Geriatr Cogn Disord 2010; 30: 205-211
67. Wallin A, Gothlin M, Gustavsson M, Zetterberg H, Eckerstrom C, Blennow K, et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement Geriatr Cogn Disord 2011; 32: 193-197
68. Eckerstrom C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, et al. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement Geriatr Cogn Disord 2010; 29: 294-300
69. Eckerstrom C, Olsson E, Bjerke M, Malmgren H, Edman A, Wallin A, et al. A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. J Alzheimers Dis 2013; 36: 421-431
70. Eckerstrom C, Olsson E, Klasson N, Berge J, Nordlund A, Bjerke M, et al. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study. J Alzheimers Dis 2014; 44: 205-214
71. Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, et al. Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011; 26: 135-142
72. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H and Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 2013; 34: 949-956
73. Rolstad S, Berg AI, Eckerstrom C, Johansson B and Wallin A. Differential impact of neurofilament light subunit on cognition and functional outcome in memory clinic patients with and without vascular burden. J Alzheimers Dis 2015; 45: 873-881
74. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002; 8: 448-460
75. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H and Wallin A. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment- proof of concept. Dement Geriatr Cogn Disord 2009; 27: 194-200
76. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H and Wallin A. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia- A follow-up report. Dement Geriatr Cogn Disord 2009; 28: 110-115
77. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Blennow K, Olesen PJ, et al. High education may offer protection against tauopathy in patients with mild cognitive impairment. J Alzheimers Dis 2010; 21: 221-228
78. Rolstad S, Berg AI, Zetterberg H, Johansson B and Wallin A. All cognitive systems but speed and visuospatial functions reduce the effect of CSF pathology on other systems. Curr Alzheimer Res 2012; 9: 1043-1049
79. Vasquez BP and Zakzanis KK. The neuropsychological profile of vascular cognitive impairment not demented: a meta-analysis. J Neuropsychol 2014; 9: 109-136
80. Aretouli E, Okonkwo OC, Samek J and Brandt J. The fate of the 0.5 s: predictors of 2-year outcome in mild cognitive impairment. J Int Neuropsychol Soc 2011; 17: 277-288
81. Aretouli E, Tsilidis KK and Brandt J. Four-year outcome of mild cognitive impairment: the contribution of executive dysfunction. Neuropsychology 2013; 27: 95-106
82. Klekociuk SZ, Summers JJ, Vickers JC and Summers MJ. Reducing false positive diagnoses in mild cognitive impairment: the importance of comprehensive neuropsychological assessment. Eur J Neurol 2014; 21: 1330-1336
83. Serrano CM, Dillon C, Leis A, Taragano FE and Allegri RF. Mild cognitive impairment: risk of dementia according to subtypes. Actas Esp Psiquiatr 2013; 41: 330-339
84. Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, et al. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. Dement Geriatr Cogn Disord 2013; 36: 1-19
85. O'Brien JT, Firbank MJ, Krishnan MS, van Straaten EC, van der Flier WM, Petrovic K, et al. White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS study. Am J Geriatr Psychiatry 2006; 14: 834-841
86. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010; 41: 1278-1284
87. Heister D, Brewer JB, Magda S, Blennow K and McEvoy LK. Alzheimer's Disease Neuroimaging I. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77: 1619-1628
88. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012; 33: 2272-2281
89. Shi F, Liu B, Zhou Y, Yu C and Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: meta-analyses of MRI studies. Hippocampus 2009; 19: 1055-1064
90. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG and Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990; 81: 323-326
91. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, et al. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 2004; 35: e159-e162
92. Candelario-Jalil E, Thompson J, Taheri S, Grossetete M, Adair JC, Edmonds E, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke 2011; 42: 1345-1350
93. Rosenberg GA, Bjerke M and Wallin A. Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke 2014; 45: 1531-1538
94. Brinkmalm A, Brinkmalm G, Honer WG, Frolich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener 2014; 9: 53
95. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012; 22: 1993-2004
96. Dumurgier J, Paquet C, Benisty S, Kiffel C, Lidy C, Mouton-Liger F, et al. Inverse association between CSF Abeta 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory. Neurobiol Dis 2010; 40: 456-459
97. Soldan A, Pettigrew C, Li S, Wang MC, Moghekar A, Selnes OA, et al. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging 2013; 34: 2827-2834
98. Blennow K, Wallin A, Fredman P, Gottfries CG, Karlsson I and Svennerholm L. Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur Neuropsychopharmacol 1990; 1: 79-81
99. Blennow K, Wallin A, Gottfries CG, Lekman A, Karlsson I, Skoog I, et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992; 13: 107-113
100. Wallin A, Blennow K and Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996; 7: 267-272
101. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12: 255-260
102. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009; 30: 682-690
103. Kruczyk M, Zetterberg H, Hansson O, Rolstad S, Minthon L, Wallin A, et al. Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. J Neural Transm 2012; 119: 821-831
104. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, et al. CSF biomarkers for Alzheimer's pathology and the effect size of APOE varepsilon4. Mol Psychiatry 2013; 19: 148-149
105. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K and Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-1964
106. Sjogren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001; 12: 257-264
107. Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener 2011; 6: 69
108. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011; 13: 151-159
109. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009; 16: 389-397
110. Ewers M, Zhong Z, Burger K, Wallin A, Blennow K, Teipel SJ, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008; 131 (Pt 5): 1252-1258
111. Wallin A, Blennow K, Fredman P, Gottfries CG, Karlsson I and Svennerholm L. Intrathecal synthesis of immunoglobulin G in vascular dementia. Acta Neurol Scand 1990; 81: 168-172
112. Wallin A, Blennow K, Edman A and Mansson JE. Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia. Int Psychogeriatr 1996; 8: 425-436
113. Wallin A, Sjogren M, Blennow K and Davidsson P. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2003; 16: 200-207
114. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69: 2205-2212
115. Thorvaldsson V, Nordlund A, Reinvang I, Blennow K, Zetterberg H, Wallin A, et al. Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42. Int Psychogeriatr 2010; 22: 598-606.